Nearly one in seven men (one in five African-American men) will be diagnosed with prostate cancer in their lifetime
— Prostate cancer is the most common cancer among men. In an effort to increase awareness of the disease and the benefits of early screening, the National Football League Alumni Association (NFLA), Cancer Treatment Centers of America® (CTCA) and LabCorp® are teaming up to educate men and increase access to screenings. Beginning Sept. 1 through Oct. 15, 2,000 men, ages 40 and older, who meet eligibility requirements, may sign up to receive a free Prostate Specific Antigen (PSA) screening by LabCorp at any of its 1,750 locations throughout the U. S. After the first 2,000 free PSA screening spots are filled, eligible men may still schedule a screening at the discounted price of $25 throughout the sign-up period. Screenings must be performed within six months of the sign-up date.
“I know several colleagues and friends who have been diagnosed with prostate cancer,” Edwards said. “First, the former owner of the Kansas City Chiefs, Lamar Hunt, who sadly lost his fight, and my father-in-law who was diagnosed eight years ago and had prostate surgery. We’re hoping this campaign will raise awareness of the need to get screened.”
A national kick-off press conference will be held Aug. 30 at 1 p.m. ET at NFL Films in Mount Laurel, New Jersey, with Edwards and former defensive back and five-time Emmy award winner Beasley Reece. Also speaking at the event will be Interim President & CEO Elvis Gooden and former NFL players, Mike Quick and Jon Runyan. Quick’s father battled prostate cancer for several years and Runyan, a former U.S. Representative, is a strong prostate cancer awareness advocate.
Sean Cavanaugh, MD, Chief of Radiation Oncology at CTCA® at Southeastern Regional Medical Center, Gary M. Huff, CEO of LabCorp Diagnostics and Carl Baylor, a stage IV metastatic prostate cancer survivor and advocate for early PSA screening, also will be in attendance. Additionally, campaign events will be held in conjunction with the Cancer Treatment Centers of America hospitals in each of the following cities:
“Screening is the first defense against prostate cancer,” Cavanaugh said. “That’s why we are proud to work with the NFLA and LabCorp to raise awareness about the importance of screening, as well as advances in screening techniques, diagnosis and treatment options, including active surveillance, for prostate cancer. A PSA test that falls outside a specific range considered normal does not always mean cancer and it does not dictate the type of treatment you receive. However, a high PSA level may indicate increased risk for cancer and should be discussed promptly with a physician.”
Eligible men may order their free or discounted PSA screening by visiting Prostate Pep Talk or Health Testing Centers – Prostate Pep Talk. Testing will be performed by LabCorp at any of LabCorp’s patient service center locations across the country. Men who have an elevated PSA outside a specific range considered normal may be at increased risk for cancer and should consult with their physician to determine the next steps that best suit their needs. Elevated PSA levels do not always indicate prostate cancer.
“LabCorp is pleased to team up with the NFLA and Cancer Treatment Centers of America to increase awareness of prostate cancer and provide free and reduced-cost PSA screenings,” said Huff. “The Prostate Pep Talk campaign will help to improve health and improve lives for men across the country. Getting a PSA screening will help men and their loved ones make more informed monitoring and treatment decisions.”
For more information visit Prostate Pep Talk.
About the NFL Alumni Association
The NFL Alumni Association is a nationwide group of former NFL players, coaches, staffers, cheerleaders, spouses and associate members whose mission is to serve, assist and inform former players and their families. The Association offers a variety of medical, financial and social programs to help members lead healthy, productive and connected lives, as well as community initiatives under its “Caring for Kids” programs. For more information please visit www.nflalumni.org.
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Reflecting our patient-centered approach to cancer care, our patient satisfaction scores consistently rank among the highest in the country for cancer care providers, and CTCA is also rated one of the most admired hospital systems in the country in national consumer surveys. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.